Case Study: Sponsor achieves compliant rare disease data anonymization with Real Life Sciences

Sponsor achieves Health Canada’s 0.09 risk threshold with Real Life Sciences

The customer, a sponsor, faced significant challenges in anonymizing clinical trial data for rare disease populations. The small patient groups inherent to these trials increased the risk of patient re-identification, creating compliance hurdles and potential delays with regulators. The sponsor partnered with Real Life Sciences to develop a robust strategy for data transformation that would meet strict regulatory requirements.

Real Life Sciences implemented a comprehensive solution involving advanced anonymization and quantifiable risk modeling performed ahead of the initial regulatory meeting. This proactive approach provided immediate alignment with Health Canada's expectations and successfully achieved their 0.09 risk threshold. The vendor also authored a whitepaper detailing best practices, which the sponsor used to streamline internal processes and train cross-functional teams, ultimately avoiding time-consuming rework and simplifying future submissions.

Sponsor